FBRX
Forte Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$76.99
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | (9.0K) | 64.0K | 39.0K | 9.0K | — |
| Gross Profit | 9.0K | (64.0K) | (39.0K) | (9.0K) | — |
| Operating Expenses | |||||
| R&D Expense | 57.0M | 58.2M | 21.2M | 21.9M | 5.6M |
| SG&A Expense | 10.3M | 12.4M | 15.4M | 10.6M | 8.3M |
| General & Admin Expense | 10.3M | 12.4M | — | 10.6M | 8.3M |
| Selling & Marketing Expense | — | — | — | (9.0K) | — |
| Other Expenses | 22.8M | — | — | (0.00) | 17.0K |
| Total Operating Expenses | 90.0M | 70.7M | 36.6M | 32.5M | 13.9M |
| Cost and Expenses | 90.0M | 70.7M | 36.6M | 32.5M | 13.9M |
| Operating Income (EBIT) | (90.0M) | (70.7M) | (36.6M) | (32.5M) | (13.9M) |
| Non-Operating | |||||
| Interest Income | — | 2.7M | 1.3M | 1.1M | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | 2.7M | 1.3M | 1.1M | — |
| Other Non-Op Income/Expense | 3.7M | 2.3M | 1.1M | 1.0M | 17.0K |
| Non-Operating Income (excl Interest) | (3.7M) | (2.3M) | (1.1M) | (1.0M) | (17.0K) |
| EBT (Pre-Tax Income) | (86.3M) | (68.3M) | (35.5M) | (31.5M) | (13.9M) |
| Income Tax Expense | 1.6M | 1.0M | — | — | — |
| Bottom Line | |||||
| Net Income | (87.9M) | (69.4M) | (35.5M) | (31.5M) | (13.9M) |
| Earnings from Cont. Ops | (87.9M) | (69.4M) | (35.5M) | (31.5M) | (13.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (87.9M) | (69.4M) | (35.5M) | (31.5M) | (13.9M) |
| Per Share | |||||
| Basic EPS | ($4.59) | ($4.71) | ($12.17) | ($24.92) | ($19.96) |
| Diluted EPS | ($4.59) | ($4.71) | ($12.17) | ($24.92) | ($19.96) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 23.8M | 14.7M | 2.9M | 1.3M | 695341 |
| Diluted Shares Outstanding | 23.8M | 14.7M | 2.9M | 1.3M | 695341 |
| Profitability Metrics | |||||
| EBITDA | (86.3M) | (68.3M) | (35.4M) | (31.5M) | (13.8M) |
| D&A | 55.0K | 64.0K | 39.0K | 9.0K | 36.0K |
| EBIT | (86.3M) | (68.3M) | (35.5M) | (31.5M) | (13.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026